1 results match your criteria: "Affiliated to Nanjing University of Chinese Medicine Nanjing 210003[Affiliation]"
Identification of molecular targets and underlying mechanisms of Fuzheng Shengbai Decoction against colon cancer based on network pharmacology.
Am J Transl Res
September 2024
Department of Oncology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine Nanjing 210003, Jiangsu, China.
Article Synopsis
- - This study aimed to explore how Fuzheng Shengbai Decoction (FZSBD) targets and affects colon cancer at a molecular level.
- - Using network pharmacology, researchers identified 912 potential targets linked to FZSBD, highlighting five key genes (TP53, MYC, VEGFA, CCND1, IL1B) that play critical roles in immune response and the cell cycle.
- - FZSBD was found to significantly inhibit colon cancer cell growth, migration, and invasion, and when added to standard XELOX treatment, it improved immune response and reduced inflammation in patients.